Core Viewpoint - The company, Yuandong Biopharmaceutical Co., Ltd., is planning a non-public transfer of shares amounting to 3,369,550 shares, which represents 1.91% of its total share capital, to institutional investors through a pricing inquiry process [2][5]. Group 1: Share Transfer Details - The shareholders participating in the share transfer are Chengdu Nanyuan Investment Partnership, Chengdu Zhuyuan Investment Partnership, and Chengdu Juyuan Investment Partnership [2]. - The controlling shareholder and actual controller of the company will not participate in this share transfer, ensuring that their shares remain intact [2][3]. - The transfer is being organized by CITIC Securities, and the shares have been released from any restrictions, confirming clear ownership [3][4]. Group 2: Pricing and Transfer Conditions - The total number of shares to be transferred is 3,369,550, with the transfer price being set at a minimum of 70% of the average trading price over the 20 trading days prior to July 22, 2025 [5][6]. - The transfer process will prioritize price, quantity, and time of submission for determining the allocation of shares among interested institutional investors [7]. Group 3: Investor Eligibility - Eligible investors for this share transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [8]. Group 4: Company Status and Risks - The company does not face any operational risks or potential changes in control due to this share transfer, and there are no other undisclosed significant matters [9].

证券代码：688513 证券简称：苑东生物 公告编号：2025-050 成都苑东生物制药股份有限公司 股东询价转让计划书 成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）（以下合称"出让方"）保证向成都苑东生物 制药股份有限公司（以下简称"公司"或"苑东生物"）提供的信息内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担 法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ? 拟参与苑东生物首发前股东询价转让（以下简称"本次询价转让"）股东 为成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）； ? 公司控股股东、实际控制人直接或间接持有的股份不参与本次询价转让； ? 本次询价转让为非公开转让，不会通过集中竞价交易方式进行。受让方 通过询价转让受让的股份，在受让后 6 个月内不得转让； ? 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出 ...

中信证券股份有限公司 关于成都苑东生物制药股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 中信证券股份有限公司（以下简称"中信证券"）受成都苑东生物制药股份 有限公司（以下简称"苑东生物"）股东成都楠苑投资合伙企业（有限合伙）、 成都竹苑投资合伙企业（有限合伙）、成都菊苑投资合伙企业（有限合伙）（以 下简称"出让方"）委托，组织实施本次苑东生物首发前股东向特定机构投资者 询价转让（以下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则（2025 年 4 月修订）》《上海证券交易所科创板上市公司自律监管指引第 4 号——询价 转让和配售（2025 年 3 月修订）》（以下简称"《询价转让和配售指引》"）等 相关规定，中信证券对参与本次询价转让股东的相关资格进行核查，并出具本核 查意见。 一、本次询价转让的委托 中信证券收到出让方关于本次询价转让的委托，委托中信证券组织实施本次 询价转让。 二、关于参与本次询价转让股东相关 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-050 成都苑东生物制药股份有限公司 股东询价转让计划书 成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）（以下合称"出让方"）保证向成都苑东生物 制药股份有限公司（以下简称"公司"或"苑东生物"）提供的信息内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担 法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 拟参与苑东生物首发前股东询价转让（以下简称"本次询价转让"）股东 为成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）； 公司控股股东、实际控制人直接或间接持有的股份不参与本次询价转让； 本次询价转让为非公开转让，不会通过集中竞价交易方式进行。受让方 通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中信证券 ...

苑东生物公告，成都楠苑投资合伙企业(有限合伙)、成都竹苑投资合伙企业(有限合伙)、成都菊苑投资 合伙企业(有限合伙)计划参与公司首发前股东询价转让，拟转让股份总数为336.95万股，占公司总股本 的1.91%。本次询价转让为非公开转让，受让方通过询价转让受让的股份在受让后6个月内不得转让。 受让方为具备相应定价能力和风险承受能力的机构投资者。转让原因为自身资金需求，价格下限不低于 发送认购邀请书之日(2025年7月22日)前20个交易日股票交易均价的70%。 ...

688513 2025 Chengdu Easton Biopharmaceuticals Co.,Ltd. 8 610219 成都苑东生物制药股份有限公司 2025 年第一次临时股东大会会议资料 成都苑东生物制药股份有限公司 2025 年第一次临时股东大会会议资料目录 | 2025 年第一次临时股东大会会议资料目录. | | --- | | 2025 年第一次临时股东大会会议须知 | | 2025 年第一次临时股东大会会议议程 | | 2025 年第一次临时股东大会会议议案 | | 议案 1:《关于免去彭龙先生独立董事职务的议案》 | | 议案 2: 《关于补选公司第四届董事会独立董事的议案》 | 2 / 8 2025 2025 " " " " 2025 3 " " " " " " / 5 3 / 8 2025 / " " " " " " https://vote.sseinfo.com/i/yjt_help.pdf 4 / 8 2025 2025 1 2025 8 1 14 00 2 8 3 4 2025 8 1 2025 8 1 2025 8 1 9:15-9:25 9:30-11:30 13:00-1 ...

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF (嘉实) showed an intraday turnover of 18.19%, with a transaction volume of 40.9491 million yuan, indicating active market trading [3] - Over the past week, the Kexin Pharmaceutical ETF (嘉实) experienced a scale increase of 16.9597 million yuan, ranking first among comparable funds [3] - The Kexin Pharmaceutical ETF (嘉实) saw a share increase of 7.5 million shares over the past week, also ranking first among comparable funds [3] - As of July 21, the Kexin Pharmaceutical ETF (嘉实) has achieved a net value increase of 43.45% over the past year, placing it in the top 16.56% among 2,929 index equity funds [3] Group 2: Stock Performance - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading stocks including 联影医疗 (9.73%), 百济神州 (6.04%), and 惠泰医疗 (5.69%) [5][3] - The highest monthly return since inception for the Kexin Pharmaceutical ETF (嘉实) was 23.29%, with the longest consecutive monthly increase being 5 months and an average monthly return of 7.43% [3] Group 3: Market Trends - Huazhong Securities maintains a bottom-up view of the pharmaceutical sector, emphasizing the importance of hard technology innovations, particularly in innovative drugs and devices, which are becoming market hotspots [6] - The recent announcement from the Shanghai Sunshine Pharmaceutical Procurement Network regarding the 11th batch of national centralized procurement includes 55 drug varieties, with key principles focusing on stability, quality assurance, and anti-competitive practices [5]

截至7月18日，国泰创新医疗混合发起A近三个月复权单位净值增长率为31.99%，位于同类可比基金53/138；近半年复权单位净值增长率为54.88%，位于同 类可比基金44/138；近一年复权单位净值增长率为54.11%，位于同类可比基金41/133。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比较情况。图为坐标原点到区间内某时点的净值增长率在同类基金中的分位数。 AI基金国泰创新医疗混合发起A（018159）披露2025年二季报，第二季度基金利润149.28万元，加权平均基金份额本期利润0.1153元。报告期内，基金净值 增长率为13.44%，截至二季度末，基金规模为1261.4万元。 该基金属于偏股混合型基金，长期投资于医药医疗股票。截至7月18日，单位净值为1.117元。基金经理是邱晓旭，目前管理3只基金近一年均为正收益。其 中，截至7月18日，国泰创新医疗混合发起A近一年复权单位净值增长率最高，达54.11%；国泰产业精选混合A最低，为13.57%。 基金管理人在二季报中表示，在基金操作上，随着 2024 年 9 月末 A/H 股票市场史诗级反弹，我们力争做好从普涨到主线的切换， ...

Group 1: Shareholder Actions - Shareholder Shen Yougen plans to transfer 159 million shares of Dongfang Caifu, accounting for 1% of the company's total share capital [2] - Major shareholder Suzhou International Development Group and its affiliates are among the specific targets for East Wu Securities' planned A-share issuance, which aims to raise up to 6 billion yuan [2] - Longhong High-Tech intends to acquire 100% equity of Guangxi Changke through a combination of share issuance, convertible bonds, and cash payments [2] Group 2: Corporate Performance - Nanjing Gaoke reported a contract sales amount of 1.021 billion yuan for the first half of 2025, representing a year-on-year increase of 729.83% [3] - The company achieved a contract sales area of 68,500 square meters in the first half of 2025, up 2437.04% year-on-year [3] Group 3: Management Changes and Legal Issues - Chairman Guo Baichun of Yaqi International has been detained for suspected embezzlement and abuse of power, but the company's operations remain normal [3] - *ST Yazhen announced that its verification work has been completed, and its stock will resume trading on July 21 [3] Group 4: Financial Performance Forecasts - Jiabiyou expects a 57.61% year-on-year increase in net profit for the first half of 2025 [7] - SF Holding reported a 14.24% year-on-year increase in revenue from its express logistics business for June 2025 [7] - Double杰 Electric anticipates a net profit increase of 16.03% to 39.23% for the first half of 2025 [7]

Group 1 - The core viewpoint of the news is the performance and management changes of Guotou Ruijin Fund's healthcare mixed fund, which has seen a decrease in net assets and changes in fund management personnel [1][2][3] Group 2 - As of June 30, 2025, the net assets of Guotou Ruijin Healthcare Mixed C Fund (011082) were 0.15 billion RMB, a decrease of 9.00% compared to the previous period [1] - The fund manager, Liu Zexu, has a background as an industry analyst at CITIC Securities and Shanghai Jinglin Asset Management before joining Guotou Ruijin Fund Management in June 2023 [1] - Recent changes in fund share scale show that the total share at the end of the period was 0.02 billion, with a net asset change rate of -24.80% [2] - The fund's performance over the last three months yielded a return of 15.46%, while the one-year return was 30.33%, and since inception, the return has been -26.81% [2] - The top ten stock holdings of the fund include companies like Heng Rui Medicine and Ke Lun Pharmaceutical, with a total holding percentage of 38.69% [2] - Guotou Ruijin Fund Management Company was established in June 2002, located in Shanghai, with a registered capital of 100 million RMB [2]